180 related articles for article (PubMed ID: 24467565)
1. Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes.
Biester T; Blaesig S; Remus K; Aschemeier B; Kordonouri O; Granhall C; Søndergaard F; Kristensen NR; Haahr H; Danne T
Pediatr Diabetes; 2014 Feb; 15(1):27-33. PubMed ID: 24467565
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes.
Biester T; Danne T; Bläsig S; Remus K; Aschemeier B; Kordonouri O; Bardtrum L; Haahr H
Pediatr Diabetes; 2016 Dec; 17(8):642-649. PubMed ID: 26782928
[TBL] [Abstract][Full Text] [Related]
3. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
Korsatko S; Deller S; Mader JK; Glettler K; Koehler G; Treiber G; Urschitz M; Wolf M; Hastrup H; Søndergaard F; Haahr H; Pieber TR
Drugs Aging; 2014 Jan; 31(1):47-53. PubMed ID: 24263619
[TBL] [Abstract][Full Text] [Related]
4. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.
Brunner M; Pieber T; Korsatko S; Kojzar H; Svendsen AL; Haahr H
Drugs Aging; 2015 Jul; 32(7):583-90. PubMed ID: 26088815
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
Hompesch M; Morrow L; Watkins E; Roepstorff C; Thomsen HF; Haahr H
Clin Ther; 2014 Apr; 36(4):507-15. PubMed ID: 24508419
[TBL] [Abstract][Full Text] [Related]
7. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
Heise T; Hermanski L; Nosek L; Feldman A; Rasmussen S; Haahr H
Diabetes Obes Metab; 2012 Sep; 14(9):859-64. PubMed ID: 22594461
[TBL] [Abstract][Full Text] [Related]
8. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.
Nosek L; Coester HV; Roepstorff C; Thomsen HF; Kristensen NR; Haahr H; Heise T
Clin Drug Investig; 2014 Sep; 34(9):673-9. PubMed ID: 25124362
[TBL] [Abstract][Full Text] [Related]
9. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
[TBL] [Abstract][Full Text] [Related]
10. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
[TBL] [Abstract][Full Text] [Related]
11. [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
Lüdemann J; Milek K; Wilhelm B; Segner A; Jaeckel E
MMW Fortschr Med; 2014 Oct; 156 Suppl 3():89-97. PubMed ID: 25417447
[TBL] [Abstract][Full Text] [Related]
12. Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.
Koehler G; Heller S; Korsatko S; Roepstorff C; Rasmussen S; Haahr H; Pieber TR
Diabetologia; 2014 Jan; 57(1):40-9. PubMed ID: 24057153
[TBL] [Abstract][Full Text] [Related]
13. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
Birkeland KI; Home PD; Wendisch U; Ratner RE; Johansen T; Endahl LA; Lyby K; Jendle JH; Roberts AP; DeVries JH; Meneghini LF
Diabetes Care; 2011 Mar; 34(3):661-5. PubMed ID: 21270174
[TBL] [Abstract][Full Text] [Related]
14. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
Heise T; Nosek L; Bøttcher SG; Hastrup H; Haahr H
Diabetes Obes Metab; 2012 Oct; 14(10):944-50. PubMed ID: 22726241
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of insulin degludec.
Vora J; Cariou B; Evans M; Gross JL; Harris S; Landstedt-Hallin L; Mithal A; Rodriguez MR; Meneghini L
Diabetes Res Clin Pract; 2015 Jul; 109(1):19-31. PubMed ID: 25963320
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
Korsatko S; Deller S; Koehler G; Mader JK; Neubauer K; Adrian CL; Thomsen H; Haahr H; Pieber TR
Clin Drug Investig; 2013 Jul; 33(7):515-21. PubMed ID: 23749405
[TBL] [Abstract][Full Text] [Related]
17. A review of the pharmacological properties of insulin degludec and their clinical relevance.
Haahr H; Heise T
Clin Pharmacokinet; 2014 Sep; 53(9):787-800. PubMed ID: 25179915
[TBL] [Abstract][Full Text] [Related]
18. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.
Heise T; Korsatko S; Nosek L; Coester HV; Deller S; Roepstorff C; Segel S; Kapur R; Haahr H; Hompesch M
J Diabetes; 2016 Jan; 8(1):132-8. PubMed ID: 25581159
[TBL] [Abstract][Full Text] [Related]
19. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
Heise T; Kaplan K; Haahr HL
J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
[TBL] [Abstract][Full Text] [Related]
20. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial.
Danne T; Datz N; Endahl L; Haahr H; Nestoris C; Westergaard L; Fjording MS; Kordonouri O
Pediatr Diabetes; 2008 Dec; 9(6):554-60. PubMed ID: 18761644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
